Leucine

Leucine

SCHEMBL7375203

CC(C)C[C@H](N)C(=O)O.CCCc1ccc(CC[C@@H](NCCC(=O)O)C(=O)O)cc1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP3 P08254 3/20 0.46
MMP2 P08253 2/20 0.46
S1PR1 P21453 3/20 0.42
S1PR2 O95136 2/20 0.42
S1PR3 Q99500 1/20 0.42
SLC7A5 Q01650 1/20 0.41
MAPT P10636 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
ERAP2 Q6P179 1/20 0.39
ERAP1 Q9NZ08 1/20 0.39
LNPEP Q9UIQ6 1/20 0.39
KIF11 P52732 1/20 0.39
NOD1 Q9Y239 1/20 0.38
LTA4H P09960 1/20 0.37
ACE P12821 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Leucine SCHEMBL7383434 0.93 SLC7A5 (0.41) MMP3MMP2S1PR1S1PR2S1PR3
Leucine SCHEMBL7383856 0.91 MMP8 (0.44) MMP3MMP2S1PR1S1PR2S1PR3
Leucine SCHEMBL6415294 0.91 LTA4H (0.46) MMP3SLC7A5ERAP2ERAP1LNPEP
Leucine SCHEMBL7382855 0.90 LMNA (0.45) MMP3MMP2SLC7A5ERAP2ERAP1
Leucine SCHEMBL7378736 0.83 MASP2 (0.43) MMP3MMP2SLC7A5ERAP2ERAP1
Leucine SCHEMBL7364033 0.82 SLC7A5 (0.44) MMP3MMP2SLC7A5MAPTTAS1R3
Leucine SCHEMBL6418640 0.82 SLC7A5 (0.44) MMP3MMP2SLC7A5MAPTTAS1R3
Leucine SCHEMBL7322429 0.81 SLC7A5 (0.55) MMP3MMP2S1PR1S1PR2S1PR3
Arginine SCHEMBL7432757 0.81 NOD1 (0.41) S1PR1S1PR2S1PR3L3MBTL1KIF11
Norleucine SCHEMBL7430731 0.81 NOD1 (0.48) S1PR1S1PR2S1PR3NOD1LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1098662-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2001-05-16 EP disclosed
EP-1047450-A1 ACE INHIBITOR-MMP INHIBITOR COMBINATIONS WARNER-LAMBERT COMPANY (US) 2000-11-02 EP disclosed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 WO disclosed
EP-0946166-A1 USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING WARNER-LAMBERT COMPANY (US) 1999-10-06 EP disclosed
WO-1999032150-A1 ACE INHIBITOR-MMP INHIBITOR COMBINATIONS WARNER-LAMBERT COMPANY (US) 1999-07-01 WO disclosed
WO-1998026773-A1 USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING WARNER-LAMBERT COMPANY (US) 1998-06-25 WO disclosed